Leptomeningeal Metastasis

Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Plus Therapeutics
2 programs
2
186RNLPhase 11 trial
186RNLPhase 11 trial
Active Trials
NCT07098806Recruiting24Est. Oct 2031
NCT05034497Active Not Recruiting18Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Plus Therapeutics186RNL
Plus Therapeutics186RNL

Clinical Trials (2)

Total enrollment: 42 patients across 2 trials

Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Start: Jul 2025Est. completion: Oct 203124 patients
Phase 1Recruiting

Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Start: Dec 2021Est. completion: Jun 202618 patients
Phase 1Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 42 patients
1 companies competing in this space